| P50 | author | Jürgen Popp | Q21033130 |
| | Dana Cialla-May | Q56045735 |
| | Shimaa Eissa | Q84567386 |
| | Karina Weber | Q89342205 |
| | Maher M Aljohani | Q91304936 |
| P2093 | author name string | Omar A Alsager | |
| | Mohammed Zourob | |
| | Raja Chinnappan | |
| P2860 | cites work | Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants | Q26743614 |
| | Small-Molecule Binding Aptamers: Selection Strategies, Characterization, and Applications | Q26744499 |
| | A specific antidote for dabigatran: functional and structural characterization | Q27684149 |
| | Dabigatran, bleeding, and the regulators | Q28244581 |
| | Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity | Q28278166 |
| | 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society | Q29614693 |
| | Aptamers and their biological applications | Q30470240 |
| | RNA aptamers as reversible antagonists of coagulation factor IXa. | Q33344114 |
| | Gonyautoxin 1/4 aptamers with high-affinity and high-specificity: From efficient selection to aptasensor application. | Q53201395 |
| | Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations. | Q53342787 |
| | Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. | Q53468814 |
| | Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application | Q81873110 |
| | Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran | Q85232153 |
| | Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants | Q85558713 |
| | Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial a | Q86047624 |
| | Direct thrombin inhibitors. | Q33393692 |
| | Aptamers and the next generation of diagnostic reagents | Q33615065 |
| | Nucleic acid aptamers: clinical applications and promising new horizons | Q34028112 |
| | Thrombosis: a major contributor to global disease burden. | Q34442924 |
| | Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor | Q34611004 |
| | Aptamer-based label-free impedimetric biosensor for detection of progesterone. | Q35500014 |
| | Generation of an anti-Dabigatran Monoclonal Antibody and Its Use in a Highly Sensitive and Specific Enzyme-Linked Immunosorbent Assay for Serum Dabigatran | Q35539271 |
| | Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752598 |
| | UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays | Q35877331 |
| | Coagulation assessment with the new generation of oral anticoagulants | Q36968781 |
| | Anticoagulating obese patients in the modern era. | Q37919151 |
| | New anticoagulants and antiplatelet agents: a primer for the clinical gastroenterologist | Q38176801 |
| | Enzyme-linked, aptamer-based, competitive biolayer interferometry biosensor for palytoxin | Q38290229 |
| | DNA aptamers selection and characterization for development of label-free impedimetric aptasensor for neurotoxin anatoxin-a | Q38301673 |
| | Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures. | Q38332219 |
| | Epidemiology of venous thromboembolism | Q41667853 |
| | The discovery of dabigatran etexilate | Q41842059 |
| | Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study | Q46176054 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dabigatran | Q419345 |
| P304 | page(s) | 13290 | |
| P577 | publication date | 2018-09-05 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate | |
| P478 | volume | 8 | |